• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Endometriosis - Pipeline Review, H1 2012 Product Image

Endometriosis - Pipeline Review, H1 2012

  • Published: February 2012
  • 69 pages
  • Global Markets Direct

Endometriosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Endometriosis - Pipeline Review, H1 2012', provides an overview of the Endometriosis therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. 'Endometriosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Endometriosis.
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endometriosis Overview
Therapeutics Development
An Overview of Pipeline Products for Endometriosis
Endometriosis Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Endometriosis Therapeutics – Products under Development by Companies
Companies Involved in Endometriosis Therapeutics Development
Abbott Laboratories
Euroscreen S.A.
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Kissei Pharmaceutical Co., Ltd.
Addex Pharmaceuticals
AEterna Zentaris Inc.
Soligenix, Inc.
Repros Therapeutics Inc.
Peptron, Inc.
Meditrina Pharmaceuticals, Inc.
PregLem SA
Isifer AB
Endometriosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-385 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elagolix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX68692 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GnRH Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proellex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LPM Leuprolide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs For Prostate Cancer & Endometriosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGL2001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPI-676 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP1707 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endometriosis Therapeutics – Drug Profile Updates
Endometriosis Therapeutics – Discontinued Products
Endometriosis Therapeutics - Dormant Products
Endometriosis – Product Development Milestones
Featured News & Press Releases
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids
Jan 03, 2012: Repros Completes Dosing In Phase II Low-Dose Oral Proellex Trial
Nov 03, 2011: ValiRx Files New Patent For VAL201 For Further Indication In Endometriosis
Oct 04, 2011: Neurocrine Receives Second Milestone Payment Of $20m Under Abbott Collaboration Agreement
Sep 27, 2011: Neurocrine Announces Elagolix Scientific Presentations At 67th Annual Meeting Of American Society For Reproductive Medicine
Sep 20, 2011: Repros Commences Dosing Of Last Cohort In Oral Proellex Low Dose Study
Aug 29, 2011: Takeda Initiates Phase II Clinical Trials Of TAK-385 In Japan
Jun 23, 2011: Repros Enrolls Fourth Cohort In Low Dose Proellex Study
Jun 16, 2011: Neurocrine Announces Elagolix Scientific Presentations At 11th World Congress On Endometriosis
Mar 15, 2011: Repros Therapeutics Reports Results From Completed 1mg Dose Cohort In Low Dose Proellex Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Endometriosis, H1 2012
Products under Development for Endometriosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Abbott Laboratories, H1 2012
Euroscreen S.A., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Astellas Pharma Inc., H1 2012
Kissei Pharmaceutical Co., Ltd., H1 2012
Addex Pharmaceuticals, H1 2012
AEterna Zentaris Inc., H1 2012
Soligenix, Inc., H1 2012
Repros Therapeutics Inc., H1 2012
Peptron, Inc., H1 2012
Meditrina Pharmaceuticals, Inc., H1 2012
PregLem SA, H1 2012
Isifer AB, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Endometriosis Therapeutics – Drug Profile Updates
Endometriosis Therapeutics – Discontinued Products
Endometriosis Therapeutics – Dormant Products
Endometriosis Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Endometriosis, H1 2012
Products under Development for Endometriosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos